Literature DB >> 17011760

Metabolism of eicosanoids and their action on renal function during ischaemia and reperfusion: the effect of alprostadil.

B Dołegowska1, E Pikuła, K Safranow, M Olszewska, K Jakubowska, D Chlubek, P Gutowski.   

Abstract

Eicosanoids, active metabolites of arachidonic acid (AA), play an important role in the regulation of renal haemodynamics and glomerular filtration. Our study verified the hypothesis on the positive action of exogenously administered PGE(1) on renal function during an operation with temporary ischaemia of the lower half of the body. Also the effect of alprostadil (prostaglandin E(1) analogue) administered during the operation of an abdominal aorta aneurysm on the postoperative systemic metabolism of AA and the glomerular filtration rate (GFR) was investigated. The study included 42 patients with a diagnosed abdominal aorta aneurysm who have been qualified for the operation of implantation of the aortic prosthesis. The patients were randomly assigned to two groups: the study group (I) receiving alprostadil and the control group (II) without alprostadil. The levels of hydroxyeicosatetraenoic acids (15-HETE, 12-HETE, 5-HETE) were determined by RP-HPLC and the level of thromboxane B(2) (TxB(2)) was determined by ELISA in the plasma of the blood drawn from vena cava superior immediately before aortic clamping (A) and 5 min after aortic declamping (B). The administration of PGE(1) affects the metabolism of 15-HETE in a manner dependent on the baseline value of GFR but does not significantly change the postoperative renal function. The metabolism of 15-HETE is affected by the baseline value of GFR1 and a longer period of ischaemia is correlated with lower concentrations of 5-HETE during reperfusion. The results of our studies indicate that TxB(2) influences the postoperative function of kidneys.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17011760     DOI: 10.1016/j.plefa.2006.07.016

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  6 in total

1.  Fish oil supplementation reduces cachexia and tumor growth while improving renal function in tumor-bearing rats.

Authors:  Isabela Coelho; Fernando Casare; Danielle C T Pequito; Gina Borghetti; Ricardo K Yamazaki; Gleisson A P Brito; Marcelo Kryczyk; Luiz Claudio Fernandes; Terezila M Coimbra; Ricardo Fernandez
Journal:  Lipids       Date:  2012-09-27       Impact factor: 1.880

2.  Prevention of contrast-induced nephropathy with prostaglandin E1 in high-risk patients undergoing percutaneous coronary intervention.

Authors:  Wen-Hua Li; Dong-Ye Li; Wen-Hao Qian; Jia-Li Liu; Tong-Da Xu; Hong Zhu; Hai-Yan He
Journal:  Int Urol Nephrol       Date:  2014-02-26       Impact factor: 2.370

3.  Protective effects of mitochondrion-targeted peptide SS-31 against hind limb ischemia-reperfusion injury.

Authors:  Jing Cai; Yu Jiang; Meng Zhang; Hongting Zhao; Huihui Li; Kuanyu Li; Xin Zhang; Tong Qiao
Journal:  J Physiol Biochem       Date:  2018-03-27       Impact factor: 4.158

4.  Efficacy of alprostadil for preventing of contrast-induced nephropathy: A meta-analysis.

Authors:  Jing-Zhan Zhang; Xiao-Jing Kang; Ying Gao; Ying-Ying Zheng; Ting-Ting Wu; Long Li; Fen Liu; Yi-Ning Yang; Xiao-Mei Li; Yi-Tong Ma; Xiang Xie
Journal:  Sci Rep       Date:  2017-04-21       Impact factor: 4.379

5.  Combined use of hydration and alprostadil for preventing contrast-induced nephropathy following percutaneous coronary intervention in elderly patients.

Authors:  Rong-He Xu; Gui-Zhou Ma; Zhi-Xiong Cai; Ping Chen; Zhi-Dan Zhu; Wen-Liang Wang
Journal:  Exp Ther Med       Date:  2013-08-08       Impact factor: 2.447

6.  Effects of alprostadil and iloprost on renal, lung, and skeletal muscle injury following hindlimb ischemia-reperfusion injury in rats.

Authors:  Dilek Erer; Abdullah Özer; Hüseyin Demirtaş; İpek Işık Gönül; Halil Kara; Hande Arpacı; Faruk Metin Çomu; Gürsel Levent Oktar; Mustafa Arslan; Ayşegül Küçük
Journal:  Drug Des Devel Ther       Date:  2016-08-19       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.